Genpact Ltd.

▲ Bull Case

• ◆Analytics-mix re-rating catches up to EXLS/WNS peers. If Genpact analytics/Tech-AI revenue reaches 35% of mix by FY30 (vs. 22% today) and market awards 16× P/E (vs. 22× EXLS), FY30 EPS ~$8.50 × 16× = ~$136/share, 3-yr PV ~$108, implying +215% from current price.
• ◆AI as TAM-expander, not labor-replacer. Cora platform + GE-Capital-legacy domain knowledge position Genpact as integration layer between enterprise data and hyperscaler LLMs. Outcome-based contracts (DSO reduction, exception rates) command 20–30% pricing premium. Adjusted operating margin reaches 19.5% by FY30 (matching INFY ceiling).
• ◆Takeout optionality understated. At ~$6.5B EV, Genpact is digestible for Accenture, Capgemini, or PE (Blackstone, KKR). Historical precedent for 30–40% takeout premium provides $44–48 floor scenario even before organic rerating.

▼ Bear Case

• ◆FY25 growth was cyclical bounce, not structural turn. F&A scope-cuts from Microsoft Copilot / SAP embedded AI accelerate through FY27–28 renewals; analytics growth slows as EXLS, EPAM, and AI-native startups win incremental deals. Revenue CAGR FY26–30 lands 2.5%; FY30 EPS $5.20 × 9× = $47 (3-yr PV $37, ~flat from current).
• ◆GE-entity revenue cliff materializes late. Three independent post-spin GE entities take 4–6 years to fully review legacy BPM contracts. Cumulative scope reductions of $200M+ (including $150–200M in GE HealthCare alone) hit FY27–28. Combined with INR appreciation, margin compresses 80–150bps.
• ◆Buyback engine quietly compresses. As share price rerated from $25 to $34+, buyback yield fell from ~9% to ~6.5%. EPS-growth attribution from financial engineering halves. Story becomes 'operating growth or nothing'—and operating growth must outperform peers to justify multiple expansion. If not, multiple stays 9–10× and stock drifts sideways.

“The active sell-side debate is whether the FY25 bounce extends or fades. Bull-side analysts (Goldman, JPMorgan in Buy ratings) cite +7% management FY26 guide as evidence of sustained recovery and assign ~12× P/E target on FY27E EPS = $48–52 PT. Bear-side analysts (mostly Hold/Neutral) argue analytics segment is still ~22% of revenue (vs. EXLS's 60%+) and GE-spin contract review cycles haven't hit FY27–28 yet. Consensus median PT ~$45–48 with dispersion in FY27–28 numbers. Two falsifiable questions dominate: (a) does management break out analytics as disclosed segment in FY26 or FY27, and (b) do any three GE entities formally renew multi-year contracts.”

• ◆C1 — Quarterly earnings: analytics revenue disclosed as separate metric for first time (0–9 months, 35% probability, +5–10% magnitude)
• ◆C2 — GE-entity multi-year contract extension announced (6–18 months, 30% probability, ±5–20% magnitude)
• ◆C3 — Investor/Analyst Day with quantified Data-Tech-AI roadmap (6–18 months, 60% probability, +10–20% magnitude)
• ◆C4 — Marquee Fortune-100 new logo win in AI/analytics (6–18 months, 40% probability, +8–15% magnitude)
• ◆C5 — Two consecutive quarters of >5% organic growth confirming non-cyclical recovery (6–12 months, 60% probability, +10–15% cumulative rerating)
• ◆C6 — Strategic acquisition ($200–500M analytics company) (12–24 months, 30% probability, +10–20% if accretive)
• ◆C7 — Takeout offer at 30–40% premium (18–36 months, 20% probability, +30–50% one-time)
• ◆C8 — Analytics mix surpasses 30% of revenue by FY27 (18–24 months, 40% probability, +20–30% multiple expansion)

• ◆R1 — GenAI cannibalizes F&A faster than analytics revenue replaces it (Prob 4/5, Impact 4/5, Score 16/25) [PRIMARY]
• ◆R2 — GE-entity revenue cliff (>$150M reduction over 2–3 years) (Prob 3/5, Impact 4/5, Score 12/25)
• ◆R3 — Growth recovery proves cyclical, decelerates back to 1–2% by FY28 (Prob 3/5, Impact 4/5, Score 12/25)
• ◆R4 — Cybersecurity breach with BFSI client data (Prob 2/5, Impact 5/5, Score 10/25)
• ◆R5 — India wage inflation outpaces automation savings (Prob 5/5, Impact 2/5, Score 10/25)
• ◆R6 — INR appreciates below 80 vs. USD, causing margin compression (Prob 3/5, Impact 3/5, Score 9/25)
• ◆R7 — CEO Kalra execution risk (analyst day disappoints; senior departures) (Prob 3/5, Impact 3/5, Score 9/25)
• ◆R8 — India DPDP Act enforcement disrupts offshore delivery (Prob 2/5, Impact 4/5, Score 8/25)
• ◆R9 — Buyback paused/reduced without strategic rationale (Prob 1/5, Impact 3/5, Score 3/25)